LIFECORE BIOMEDICAL INC
Lifecore Biomedical (LFCR) is a small-cap medical materials company focused on hyaluronic acid (HA) — a naturally occurring polymer used in ophthalmic, orthopaedic, aesthetic and regenerative-medicine applications. The company operates both product lines and contract development and manufacturing (CDMO) services, supplying customised HA solutions and sterile-fill manufacturing to medical-device and pharmaceutical customers. Investors should note Lifecore’s dual exposure to product demand and outsourced manufacturing trends: stable OEM partnerships can provide recurring revenue, while product innovation and regulatory approvals can unlock new markets. At a market cap of around $253m, the stock can be more volatile than larger peers and is sensitive to customer concentration, regulatory outcomes and capital-spend cycles. Evaluate Lifecore by reviewing revenue growth, gross margins, backlog, and cash flow, and consider industry risks. This is general educational information, not personalised investment advice; values can fall as well as rise.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Lifecore Biomedical's stock, expecting it to reach a higher price soon.
Financial Health
Lifecore Biomedical is maintaining steady cash flow and book value, indicating stable financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
BRIDGEBIO PHARMA INC
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
AMNEAL PHARMACEUTICALS INC
Amneal Pharmaceuticals Inc. is an integrated generic and specialty pharmaceutical company that develops, manufactures, and markets generic and specialty pharmaceutical products.
BAUSCH HEALTH COMPANIES INC
Produces and distributes pharmaceuticals.
Baskets Featuring LFCR
Pharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: July 23, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Dual Revenue Streams
Products and CDMO services give two potential growth levers, though performance can vary with customer demand and contract timing.
Manufacturing Edge
Specialist sterile-fill and HA expertise can attract OEM partners, but operations are capital and regulation intensive.
Market Exposure
Serves ophthalmic, orthopaedic and aesthetic markets with global opportunity, yet subject to regulatory and competitive headwinds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
